Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03778619
Other study ID # MG4101-NHL-P1
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date November 28, 2018
Est. completion date October 30, 2020

Study information

Verified date July 2020
Source Green Cross LabCell Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.


Description:

This trial will consist of 3 parts; Phase 1 Maximum Tolerated Dose, Phase 1 extended cohort and Phase 2a.

For Phase 1, those who have a confirmed diagnosis of relapsed/refractory Non-Hodgkin's Lymphoma (NHL) of B-cell Origin of any subtype will be considered eligible for enrolment. Each cycle last approximately 28 days.

Once the dose of MG4101 is determined from Phase 1, Phase 2a will commence whereby two subgroups of patients will be enrolled and will similarly receive up to 6 cycles of treatment with the recommended Phase 2a dose of MG4101. The 2 subgroups are patients with indolent and aggressive NHL of B-cell origin respectively.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 9
Est. completion date October 30, 2020
Est. primary completion date April 20, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

1. Patients with relapsed or refractory NHL of B-cell origin (mature B cell lymphoma according to WHO)* who are not considered candidates for intensive anti-lymphoma therapy.

2. Patients must have received at least 1 prior systemic treatment including anti-CD20 therapy but have received no more than 4 systemic treatments and have:

1. Relapse/Progression and is not considered as a candidate for autologous stem-cell transplantation or high-dose immuno-chemotherapy with allogenic antibody transplantation.

2. Or Relapsed/progressed after high-dose immuno-chemotherapy with autologous stem-cell transplantation.

3. Or Relapsed/progressed after homoplastic stem-cell transplantation performed at least 12 weeks ago from C1V1.

- For Phase 1 - Any subtype can be enrolled. For Phase 2a - Only below subtype can be enrolled in each group. I. Indolent B-cell NHL: Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma and Marginal Zone Lymphoma II. Aggressive B-cell NHL: Diffuse Large B-cell Lymphoma De novo and Diffuse Large B-cell Lymphoma transformed

3. According to Positron Emission Tomograph(PET)-CT screening, patients having lesion/nodules =1 with major axis longer than 1.5 cm and the boundaries are clearly shown.

4. Eastern Cooperative Oncology Group score 0 or 1

5. 20 years or older. Age limit for Phase 1 is 65 and for Phase 2a 80.

6. Expected lifespan = 3 month

7. Patients signed Informed consent form

8. Earlier documented result that showed that the patient is positive for CD20 via immunophenotyping within 6 months of C1V1

9. Toxicities due to prior therapy must be stable and recovered to = Grade 1 (except for clinically non-significant toxicities such as alopecia)

10. Those patients who satisfied with following criteria in blood testing, kidney function test and liver function test:

1. Absolute neutrophil count: Absolute Neutrophil Count = 1,000/ µL (Growth factor support at least 2 weeks prior to C1V1)

2. Haemoglobin level = 8g/? (Blood transfusion at least 2 weeks prior to C1V1)

3. Platelet count =75,000/µL (Growth factor support/blood transfusion at least 2 weeks prior to C1V1)

4. Total bilirubin < 3.0?/?

5. Aspartate aminotransferase(AST) or Alanine Aminotransferase(ALT) = 2.5 x upper normal limit (UNL)

6. Creatinine clearance (as estimated by Cockcroft Gault) = 30 mL/min

Exclusion Criteria:

1. Patients considered appropriate to have stem-cell transplantation after high-dose chemotherapy as salvage therapy.

2. Patient with Central Nervous System(CNS) lymphoma or any involvement of the CNS.

3. Patients who had a prior history of another malignancy over the last 5 years.

4. Patients with impaired organ functions deemed as significant by investigators.

5. Patients who had prior allogeneic Natural Killer cell treatment.

6. Chronic or active infectious diseases required to be treated at the time of Investigational Product administration, including Cytomegalovirus(CMV) prophylactic therapy.

7. Had human immunodeficiency virus (HIV)-positive serology.

8. HBsAg or Hepatitis B virus(HBV) DNA positive or had Hepatitis C virus(HCV) antibodies

9. Patients who received anti-CD20 cancer chemotherapy or immunoglobulin within 4 weeks of C1V1.

10. Patients who received another investigational drug within 4 weeks of C1V1.

11. Patients with acute graft-versus-host disease(GvHD) =Grade 3 or extensive chronic GvHD within 2 weeks of C1V1.

12. High-dose stem cell support treatment carried out within 6 months of C1V1.

13. Radioimmunotherapy within 4 weeks of C1V1.

14. Patients with major surgery within 4 weeks of C1V1.

15. Patients required to have treatment as having severe diseases such as severe heart failure or uncontrolled severe heart disease and considered not to be appropriate to participate in this trial by investigator's decision.

16. Patients on enzyme inducing agents.

17. Patients who have a plan to have vaccination during the trial.

18. Patients with sensitivity to Interleukin-2, cyclophosphamide or fludarabine.

19. Patients with urinary outflow obstruction

20. Patients with history of abnormal cardiac or pulmonary function tests in 6 months prior to screening visit (Clinically Significant)

21. Patients with history of solid organ allografts

22. Patients with pre-existing or initial presentation of autoimmune disease or inflammatory disorders, such as Crohn's disease, scleroderma, thyroiditis, inflammatory arthritis, diabetes mellitus, oculo-bulbar myasthenia gravis, crescentic Immunoglobulin A(IgA) glomerulonephritis, cholecystitis, cerebral vasculitis, Stevens-Johnson syndrome and bullous pemphigoid, due to possible exacerbation with IL-2

23. Concomitant treatment with other cardiotoxic inducing agents

24. Patients who are allergic to Rituximab, Rituximab's excipient (sodium citrate, polysorbate 80, sodium chloride, sodium hydroxide, hydrochloric acid) or other proteins same as Rituximab.

25. From the day of participation of this trial to 12 months from the day of final administration of Investigational Product, patients who are unable or unwilling to use appropriate contraceptive methods. (Condom, diaphragm, Intrauterine Device, hormonal oral contraceptive use, or male partner with vasectomy)

26. Pregnant or lactating women. (Breast-feeding cannot be done within 12 months after final Investigational Product administration)

27. Patients suspected to have currently known or suspected alcohol abuse or drug abuse according to investigator's decision.

28. According to investigator's judgement, protocols cannot be followed.

Study Design


Intervention

Drug:
Rituximab
weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
Fludarabine
administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Cyclophosphamide
administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Biological:
MG4101(allogeneic Natural Killer cell)
administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
Drug:
Interleukin-2
1 x 10^6 IU/m2, together with MG4101

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National Univ. Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Green Cross LabCell Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I - Maximum Tolerated Dose of the dose of MG4101 in combination with Rituximab Dose-Limiting Toxicity assessment 28 days
Primary Phase II - Objective Response Rate central review by Positron Emission Tomograph-CT up to 3 years
Secondary Phase I - Objective Response Rate investigator review by Positron Emission Tomograph-CT 1 years
Secondary Phase II - Complete Response Complete Response Rate up to 3 years
Secondary Phase II -Partial Response Partial Response rate up to 3 years
Secondary Phase II - Overall Survival every 12 weeks after End Of Treatment up to 3 years
Secondary Phase II - Time To Progression every 12 weeks after End Of Treatment up to 3 years
Secondary Phase II - Time to Response every 12 weeks after End Of Treatment up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05420493 - Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1
Completed NCT00005803 - Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Active, not recruiting NCT03583424 - Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT04923789 - A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Active, not recruiting NCT03213691 - Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT06026319 - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Phase 1
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Recruiting NCT05892718 - A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors Phase 1
Active, not recruiting NCT04284774 - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Terminated NCT02420795 - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03213678 - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT02568553 - Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Phase 1
Active, not recruiting NCT03698994 - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03210662 - Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Phase 2